LX31.F · Lexicon Pharmaceuticals, Inc

-

Please sign in to comment on LX31.F

1 Comment

Admin

4 years ago

Lexicon Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 11.1% below its 200 day moving average.

From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 27.4.

Lexicon Pharmaceuticals, Inc's total revenue sank by 97.7% to $199K since the same quarter in the previous year.

Its net income has increased by 89.3% to $-5M since the same quarter in the previous year.

Finally, its free cash flow fell by 40.7% to $-34M since the same quarter in the previous year.

Based on the above factors, Lexicon Pharmaceuticals, Inc gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
ISIN	None
Sector
Industry

Market Cap	420M
PE Ratio	11.62
Target Price	None
Beta	1.46
Dividend Yield	None

ABOUT

Lexicon Pharmaceuticals, Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

LX31.F · Lexicon Pharmaceuticals, Inc

-

Lexicon Pharmaceuticals, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Lexicon Pharmaceuticals, Inc using a moving average strategy